无EGFR突变和ALK易位的老年或体力状况2分(PS2)晚期非小细胞肺癌的治疗——仍是日常挑战
本文综述无可用分子靶点(如EGFR敏感突变、ALK易位或ROS1易位)的晚期非小细胞肺癌(NSCLC)患者中,老年或体力状况2分(PS2)亚组的治疗策略。老年和PS2患者临床试验代表性不足,缺乏数据,治疗决策困难。综述总结了包括血管生成抑制剂和免疫检查点抑制剂在内的近期治疗试验数据。
要点
- 细胞毒化疗仍是无可操作分子改变晚期NSCLC的核心治疗。
- 老年(≥65岁)和PS2患者临床试验代表性不足,治疗策略优化困难。
- 综述总结血管生成抑制剂和免疫检查点抑制剂在老年或PS2患者中的数据。
核心结论
- 老年或PS2晚期NSCLC患者因临床试验数据缺乏,优化治疗策略仍具挑战性。
研究设计与样本
- 综述,聚焦无可用致癌驱动基因的老年或PS2晚期NSCLC患者,总结近期治疗试验数据。
主要发现
- 肺癌主要为老年疾病,超过三分之二患者年龄≥65岁(当前‘老年’定义)。
- 患者自评的体力状况差(poor PS)患病率可高达50%。
- 老年和PS2患者在临床试验中代表性不足。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cytotoxic chemotherapy remains the core treatment strategy for patients with advanced non-small cell lung cancer (NSCLC) with tumours that do not have actionable molecular alterations, such as epidermal growth factor receptor (EGFR)-sensitising mutations, anaplastic lymphoma kinase (ALK) translocations or ROS1 translocations. Age and performance status (PS) are two pivotal factors to guide treatment decisions regarding the use of chemotherapy in lung cancer patients. Lung cancer is predominantly a disease of the elderly, with more than two-thirds of patients aged ≥65 years, the current definition of 'elderly'. The prevalence of poor PS, as estimated by patients themselves, can be as high as 50%. Both the elderly and PS2 patients are underrepresented in clinical trials. Therefore, optimising treatment strategy for the subgroup of elderly or PS2 patients with advanced NSCLC remains challenging as a result of a paucity of clinical trial data. The current review focusses on the elderly or PS2 patients without actionable oncogenic drivers and attempts to summarise current available data on recent treatments trials including angiogenesis inhibitors and immune-checkpoint inhibitors.
引用
- Su C, Zhou F, Shen J, et al. Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - Still a daily challenge. Eur J Cancer. 2017. PMID: 28763691. doi:10.1016/j.ejca.2017.07.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。